Objective: To investigate the clinical application of inhaled acetylcysteine solution in pediatrics of a Grade Ⅲ

Level A Hospital

and assess the rationality of inpatient medical orders

so as to promote the rational application of inhaled acetylcysteine in pediatrics and ensure the safe medication of children. Methods: Retrospective analysis was performed on clinical data of pediatric inpatients received inhaled acetylcysteine solution in a Grade Ⅲ

Level A Hospital in 2021. Children were divided into two groups based on age: <2 years old group and ⩾2 years old group. Results: There were statistically significant differences between two groups in terms of gender

body weight

daily dose of inhaled acetylcysteine

and volume of medication per nebulization. However

there were no statistically significant differences in the administration frequency of inhaled acetylcysteine and duration of medication. The drug utilization index in the ⩾2 years old group was higher than that in the < 2 years old group. Inpatient medical orders for inhaled acetylcysteine solution had problems such as inappropriate drug combination

incompatible drug compatibility

and excessive or insufficient medication volume per nebulization. Conclusion: Daily dose of inhaled acetylcysteine

drug utilization index

and medication volume per nebulization increase with the age of children. Medical orders for inhaled acetylcysteine in the hospital are partially irrational and need to be standardized